Metastatic prostate cancer continues to be an incurable disease. Despite all the novel
therapies approved in the past two decades, overall patient outcomes remain relatively poor …

Immuno-positron emission tomography (immunoPET) is a molecular imaging modality
combining the high sensitivity of PET with the specific targeting ability of monoclonal …

PSMA is a transmembrane protein that is markedly overexpressed in prostate cancer,
making it an excellent target for imaging and treating patients with prostate cancer. Several …

Prostate cancer (PCa) is the most common malignancy in men of middle and older age. The
standard treatment strategy for PCa ranges from active surveillance in low-grade, localized …

The aim of this retrospective analysis was to determine prostate-specific antigen (PSA)
response, PSA progression-free survival (PFS), and overall survival (OS) in a large cohort of …

[177Lu] Lu-PSMA has recently been approved for use in the post-taxane, post-novel
hormonal-agent setting in patients with metastatic castration-resistant prostate cancer. As a …

Radioligand therapy (RLT) with 177Lu-prostate-specific membrane antigen (PSMA)
inhibitors ([177Lu] Lu-PSMA) is currently approved for patients with metastatic castration …

Purpose γ-H2AX and 53BP1 are fundamental for cellular DNA damage response (DDR)
after radiation exposure and are linked to cell repair, arrest, or apoptosis. We aimed to …

Prostate cancer remains the commonest cancer diagnosed in males and a leading cause of
cancer-related death. Men with metastatic castration-resistant prostate cancer (mCRPC) …

Introduction This study was conducted to evaluate the predictive values of volumetric
parameters and radiomic features (RFs) extracted from pretreatment 68Ga-PSMA PET and …